Clearside Biomedical Nachrichten und Aktivitäten
Präsenz
Clearside Biomedical ist ein Unternehmen, das unter dem Börsenticker CLSD (US) gelistet ist.
Führungskräfte
Siehe das Organigramm mit seine 18 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Clearside Biomedical
- George Lasezkay, Chief Executive Officer and Director
- William Humphries, Director
- Clay Thorp, Director
Letzte Veränderungen der Führungskräfte auf Clearside Biomedical
- Anthony Gibney der/die zuvor Director war, wurde zum Chairman of the Board befördert (Nachrichten veröffentlicht am 5, November 2024).
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Clearside Biomedical nachzuverfolgen.
Biotechnologie
Clearside Biomedical hat 2.351 Konkurrenten , einschließlich Eurofins (Luxemburg), Lonza (Schweiz) und Genus (Großbritannien).
Popular M&A news in Biotechnologie
- Transcarent and Accolade have merged (veröffentlicht am 9, April 2025)..
- Kashiv BioSciences hat gerade eine Spendenaktion von 150 Millionen Dollar angekündigt. (veröffentlicht am 7, April 2025).
- Atsena Therapeutics hat gerade eine Spendenaktion von 150 Millionen Dollar angekündigt. (veröffentlicht am 4, April 2025).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Clearside Biomedical
- Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore | Clearside Biomedical, Inc.- IR Site
- View more press releases Close
Social media about Clearside Biomedical
- Clearside Biomedical auf Wikipedia, Google News & Yahoo Finance
- Clearside Biomedical auf LinkedIn, Twitter & YouTube
